{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:27:36Z","timestamp":1772220456660,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inflammatory bowel disease (IBD) has been reported to be associated with hepatobiliary diseases. Previous observational and Mendelian randomization (MR) studies have suggested a causal association between IBD and primary sclerosing cholangitis (PSC). However, it is unclear whether IBD has a causal association with primary biliary cholangitis (PBC): another autoimmune liver disease. We obtained genome-wide association study (GWAS) statistics from published GWASs for PBC, UC, and CD. We screened qualified instrumental variables (IVs) based on the three major assumptions of MR. To determine the causal relationships between UC or CD and PBC, two-sample MR analyses were performed using inverse variance-weighted (IVW), MR-Egger, and weighted median (WM) methods, and sensitivity analyses were conducted to validate the robustness of the results. We also conducted reverse MR analysis to reveal the causal association between PBC and UC or CD. UC was associated with a higher risk of PBC (OR 1.35, 95% CI 1.05\u20131.73,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02) in the IVW method, and CD was associated with an increased risk of PBC (OR 1.18, 95% CI 1.03\u20131.36,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02) in IVW. The weighted median and MR-Egger regression of both diseases showed a consistent direction but were not statistically significant. Results of the reverse MR analysis did not suggest genetic susceptibility that PBC was associated with an increased risk of UC (OR 1.05, 95% CI 0.95\u20131.17,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.34) or CD (OR 1.1, 95% CI 0.99\u20131.20,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.06). The present study revealed that IBD subtypes could increase the incidence of PBC, but in turn, PBC did not increase the incidence of IBD subtypes. Understanding that IBD and PBC constitute mutual risk factors can help with the clinical management of both diseases.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-35785-2","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T05:02:56Z","timestamp":1688619776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Causal associations between inflammatory bowel disease and primary biliary cholangitis: a two-sample bidirectional Mendelian randomization study"],"prefix":"10.1038","volume":"13","author":[{"given":"Jiaxi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"issue":"7","key":"35785_CR1","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s00535-016-1223-z","volume":"51","author":"A Tanaka","year":"2016","unstructured":"Tanaka, A. et al. Changing nomenclature for PBC from \u201cprimary biliary cirrhosis\u201d to \u201cprimary biliary cholangitis\u201d. J. Gastroenterol. 51(7), 748\u2013749 (2016).","journal-title":"J. Gastroenterol."},{"issue":"6","key":"35785_CR2","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","volume":"147","author":"WJ Lammers","year":"2014","unstructured":"Lammers, W. J. et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study. Gastroenterology 147(6), 1338-1349 e15 (2014).","journal-title":"Gastroenterology"},{"issue":"10003","key":"35785_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","volume":"386","author":"EJ Carey","year":"2015","unstructured":"Carey, E. J., Ali, A. H. & Lindor, K. D. Primary biliary cirrhosis. Lancet 386(10003), 1565\u20131575 (2015).","journal-title":"Lancet"},{"issue":"3","key":"35785_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot, C. et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48(3), 871\u2013877 (2008).","journal-title":"Hepatology"},{"issue":"2\u20133","key":"35785_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","volume":"48","author":"A Floreani","year":"2015","unstructured":"Floreani, A. et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin. Rev. Allergy Immunol. 48(2\u20133), 192\u2013197 (2015).","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"9","key":"35785_CR6","first-page":"1327","volume":"40","author":"E Kotsiliti","year":"2022","unstructured":"Kotsiliti, E. Phage therapy suppresses gut inflammation in IBD. Nat. Biotechnol. 40(9), 1327 (2022).","journal-title":"Nat. Biotechnol."},{"key":"35785_CR7","doi-asserted-by":"crossref","unstructured":"Adolph, T. E., Meyer, M., Schwarzler, J., et al. The metabolic nature of inflammatory bowel diseases. Nat. Rev. Gastroenterol. Hepatol. (2022).","DOI":"10.1038\/s41575-022-00658-y"},{"issue":"10114","key":"35785_CR8","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 390(10114), 2769\u20132778 (2017).","journal-title":"Lancet"},{"issue":"10139","key":"35785_CR9","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"JK Dyson","year":"2018","unstructured":"Dyson, J. K. et al. Primary sclerosing cholangitis. Lancet 391(10139), 2547\u20132559 (2018).","journal-title":"Lancet"},{"issue":"11","key":"35785_CR10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/annrheumdis-2016-210960","volume":"76","author":"N Groot","year":"2017","unstructured":"Groot, N. et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: The SHARE initiative. Ann. Rheum. Dis. 76(11), 1788\u20131796 (2017).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"35785_CR11","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.clinre.2019.05.002","volume":"44","author":"R Liberal","year":"2020","unstructured":"Liberal, R. et al. Primary biliary cholangitis in patients with inflammatory bowel disease. Clin. Res. Hepatol. Gastroenterol. 44(1), e5\u2013e9 (2020).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"7","key":"35785_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 37(7), 658\u2013665 (2013).","journal-title":"Genet. Epidemiol."},{"issue":"8","key":"35785_CR13","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/sim.3034","volume":"27","author":"DA Lawlor","year":"2008","unstructured":"Lawlor, D. A. et al. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27(8), 1133\u20131163 (2008).","journal-title":"Stat. Med."},{"issue":"9","key":"35785_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47(9), 979\u2013986 (2015).","journal-title":"Nat. Genet."},{"issue":"Suppl 2","key":"35785_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000440754","volume":"33","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. Geoepidemiology, genetic and environmental risk factors for PBC. Dig. Dis. 33(Suppl 2), 94\u2013101 (2015).","journal-title":"Dig. Dis."},{"issue":"4","key":"35785_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden, J. et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol. 40(4), 304\u2013314 (2016).","journal-title":"Genet. Epidemiol."},{"issue":"5","key":"35785_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess, S. & Thompson, S. G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur. J. Epidemiol. 32(5), 377\u2013389 (2017).","journal-title":"Eur. J. Epidemiol."},{"issue":"2","key":"35785_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden, J., Davey, S. G. & Burgess, S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44(2), 512\u2013525 (2015).","journal-title":"Int. J. Epidemiol."},{"key":"35785_CR19","doi-asserted-by":"crossref","unstructured":"Hemani, G., Zheng, J., Elsworth, B., et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 7 (2018).","DOI":"10.7554\/eLife.34408"},{"issue":"3","key":"35785_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord, M. et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J. Crohns Colitis 10(3), 239\u2013254 (2016).","journal-title":"J. Crohns Colitis"},{"issue":"10","key":"35785_CR21","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1023\/A:1026697613173","volume":"44","author":"M Koulentaki","year":"1999","unstructured":"Koulentaki, M. et al. Ulcerative colitis associated with primary biliary cirrhosis. Dig. Dis. Sci. 44(10), 1953\u20131956 (1999).","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"35785_CR22","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.20907","volume":"42","author":"ME Gershwin","year":"2005","unstructured":"Gershwin, M. E. et al. Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. Hepatology 42(5), 1194\u20131202 (2005).","journal-title":"Hepatology"},{"issue":"1","key":"35785_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/jhep.2001.21165","volume":"33","author":"A Parikh-Patel","year":"2001","unstructured":"Parikh-Patel, A. et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 33(1), 16\u201321 (2001).","journal-title":"Hepatology"},{"issue":"4","key":"35785_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/gut.2009.184218","volume":"59","author":"MI Prince","year":"2010","unstructured":"Prince, M. I., Ducker, S. J. & James, O. F. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 59(4), 508\u2013512 (2010).","journal-title":"Gut"},{"issue":"8","key":"35785_CR25","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1097\/MIB.0000000000001167","volume":"23","author":"S Lopes","year":"2017","unstructured":"Lopes, S. et al. Looking into enteric virome in patients with IBD: Defining guilty or innocence?. Inflamm. Bowel Dis. 23(8), 1278\u20131284 (2017).","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"35785_CR26","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/hep.22567","volume":"48","author":"P Invernizzi","year":"2008","unstructured":"Invernizzi, P. et al. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. Hepatology 48(6), 1906\u20131912 (2008).","journal-title":"Hepatology"},{"issue":"11","key":"35785_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrgastro.2014.170","volume":"11","author":"JF Colombel","year":"2014","unstructured":"Colombel, J. F. Decade in review-IBD: IBD-genes, bacteria and new therapeutic strategies. Nat. Rev. Gastroenterol. Hepatol. 11(11), 652\u2013654 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"35785_CR28","first-page":"163","volume":"54","author":"T Hibi","year":"1983","unstructured":"Hibi, T. et al. Circulating antibodies to the surface antigens on colon epithelial cells in ulcerative colitis. Clin. Exp. Immunol. 54(1), 163\u2013168 (1983).","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"35785_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00042737-199805000-00016","volume":"10","author":"IE Koutroubakis","year":"1998","unstructured":"Koutroubakis, I. E. et al. Association between ulcerative colitis and systemic lupus erythematosus: Report of two cases. Eur. J. Gastroenterol. Hepatol. 10(5), 437\u2013439 (1998).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"29","key":"35785_CR30","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.3748\/wjg.v27.i29.4929","volume":"27","author":"QY Zhou","year":"2021","unstructured":"Zhou, Q. Y. et al. Autoimmune enteropathy and primary biliary cholangitis after proctocolectomy for ulcerative colitis: A case report and review of the literature. World J. Gastroenterol. 27(29), 4929\u20134938 (2021).","journal-title":"World J. Gastroenterol."},{"issue":"24","key":"35785_CR31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.21037\/atm.2016.12.43","volume":"4","author":"V Pontecorvi","year":"2016","unstructured":"Pontecorvi, V., Carbone, M. & Invernizzi, P. The, \u201cgut microbiota\u201d hypothesis in primary sclerosing cholangitis. Ann. Transl. Med. 4(24), 512 (2016).","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"35785_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2020.0028","volume":"27","author":"A Tanaka","year":"2021","unstructured":"Tanaka, A. Current understanding of primary biliary cholangitis. Clin. Mol. Hepatol. 27(1), 1\u201321 (2021).","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"35785_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","volume":"114","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Diagnosis and management of primary biliary cholangitis. Am. J. Gastroenterol. 114(1), 48\u201363 (2019).","journal-title":"Am. J. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35785-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35785-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35785-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T06:12:05Z","timestamp":1688623925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35785-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35785"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35785-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2435433\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"2 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10950"}}